Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?

Autor:	R. Gonzalez, L.J. Havrilesky, A.A. Secord, E.R. Myers, J.A. Dottino, H.A. Moss
Rok vydání:	2020
Předmět:	Oncology Obstetrics and Gynecology
Zdroj:	Gynecologic Oncology. 159:21-22
ISSN:	0090-8258
DOI:	10.1016/j.ygyno.2020.06.043
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::37fafeb02ba2307404ab118718c186b1 https://doi.org/10.1016/j.ygyno.2020.06.043 Zobrazit plný text záznamu Full Text from ScienceDirect